Neuropace Valuation
| NPCE Stock | USD 15.44 0.03 0.19% |
At this time, the firm appears to be undervalued. Neuropace secures a last-minute Real Value of $18.13 per share. The latest price of the firm is $15.44. Our model forecasts the value of Neuropace from analyzing the firm fundamentals such as Profit Margin of (0.25) %, return on equity of -1.69, and Current Valuation of 526.44 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Neuropace's valuation include:
Price Book 27.8254 | Enterprise Value | Enterprise Value Ebitda (16.94) | Price Sales 5.4317 | Enterprise Value Revenue 5.5494 |
Undervalued
Today
Please note that Neuropace's price fluctuation is somewhat reliable at this time. Calculation of the real value of Neuropace is based on 3 months time horizon. Increasing Neuropace's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Neuropace stock is determined by what a typical buyer is willing to pay for full or partial control of Neuropace. Since Neuropace is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neuropace Stock. However, Neuropace's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 15.44 | Real 18.13 | Target 19.25 | Hype 15.85 | Naive 15.99 |
The real value of Neuropace Stock, also known as its intrinsic value, is the underlying worth of Neuropace Company, which is reflected in its stock price. It is based on Neuropace's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Neuropace's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Neuropace helps investors to forecast how Neuropace stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neuropace more accurately as focusing exclusively on Neuropace's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Neuropace's intrinsic value based on its ongoing forecasts of Neuropace's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Neuropace's closest peers. If more than one evaluation category is relevant for Neuropace we suggest using both methods to arrive at a better estimate.
Neuropace Cash |
|
Neuropace Total Value Analysis
Neuropace is now forecasted to have valuation of 526.44 M with market capitalization of 515.27 M, debt of 73.34 M, and cash on hands of 92.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neuropace fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
526.44 M | 515.27 M | 73.34 M | 92.41 M |
Neuropace Investor Information
About 93.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.75. Neuropace had not issued any dividends in recent years. Based on the measurements of operating efficiency obtained from Neuropace's historical financial statements, Neuropace is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Neuropace Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neuropace has an asset utilization ratio of 84.43 percent. This indicates that the Company is making $0.84 for each dollar of assets. An increasing asset utilization means that Neuropace is more efficient with each dollar of assets it utilizes for everyday operations.Neuropace Ownership Allocation
Neuropace maintains a total of 33.31 Million outstanding shares. The majority of Neuropace outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neuropace to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neuropace. Please pay attention to any change in the institutional holdings of Neuropace as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Neuropace Profitability Analysis
The company reported the previous year's revenue of 79.91 M. Net Loss for the year was (27.14 M) with profit before overhead, payroll, taxes, and interest of 72.83 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Neuropace's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Neuropace and how it compares across the competition.
About Neuropace Valuation
The stock valuation mechanism determines Neuropace's current worth on a weekly basis. Our valuation model uses a comparative analysis of Neuropace. We calculate exposure to Neuropace's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neuropace's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 59.1 M | 42.1 M | |
| Pretax Profit Margin | (0.34) | (0.36) | |
| Operating Profit Margin | (0.27) | (0.28) | |
| Net Loss | (0.34) | (0.36) | |
| Gross Profit Margin | 0.74 | 0.58 |
Neuropace Current Valuation Indicators
Valuation refers to the process of determining the present value of Neuropace and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Neuropace we look at many different elements of the entity such as Neuropace's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neuropace, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neuropace's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neuropace's worth.Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |